GammaPod Commercialization & Clinical Adoption
Early-Stage Breast Cancer
CommercialActive
Key Facts
About Xcision Medical Systems
Xcision Medical Systems is a private, commercial-stage medical device company pioneering stereotactic radiotherapy for breast cancer with its GammaPod system. The technology, cleared by the FDA, uses a rotating multi-source Cobalt-60 system and a proprietary breast immobilization cup to deliver precise, high-dose radiation in dramatically fewer sessions than standard care. The company targets the significant global breast cancer market by offering a non-surgical, cost-effective treatment that shortens therapy from weeks to days. Xcision is actively engaging with the clinical community and advocating for supportive reimbursement policies to drive adoption.
View full company profileTherapeutic Areas
Other Early-Stage Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| MammaPrint/BluePrint Clinical Utility Expansion | Agendia | Commercial |
| Real-World Evidence (FLEX Study) | Agendia | Observational Study |
| OncoTect for Taxanes in Early-Stage Breast Cancer | Aida Oncology | Clinical Validation |
| Pathlight MRD Test | SAGA Diagnostics | Commercial |
| Signatera™ MRD (Adjuvant De-escalation) | Natera | Clinical Utility Study |